advertisement
11.3.4 Betablocker (52)
Showing records 1 to 25
Display all abstracts in classification 11.3.4 Betablocker
Search within classification 11.3.4 Betablocker73076 Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma
Mizoue S
Advances in Therapy 2017; 34: 1438-1448
73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Battistini FD
European Journal of Pharmaceutical Sciences 2017; 105: 188-194
72975 Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
Moschos MM
Drug design, development and therapy 2017; 11: 1267-1272
72774 Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients
Aihara M
Acta Ophthalmologica 2017; 95: e720-e726
72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Huang J
AAPS PharmSciTech 2017; 18: 2919-2926
73009 Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells
Zhang Y
Cornea 2017; 36: 719-724
73171 Twenty-Four-Hour Variation of Intraocular Pressure in Primary Open-Angle Glaucoma Treated with Triple Eye Drops
Itoh Y
Journal of Ophthalmology 2017; 2017: 4398494
72975 Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
Moustafa GA
Drug design, development and therapy 2017; 11: 1267-1272
73009 Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells
Kam WR
Cornea 2017; 36: 719-724
72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Peng T
AAPS PharmSciTech 2017; 18: 2919-2926
73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Tártara LI
European Journal of Pharmaceutical Sciences 2017; 105: 188-194
73171 Twenty-Four-Hour Variation of Intraocular Pressure in Primary Open-Angle Glaucoma Treated with Triple Eye Drops
Nakamoto K
Journal of Ophthalmology 2017; 2017: 4398494
73076 Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma
Nitta K
Advances in Therapy 2017; 34: 1438-1448
72774 Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients
Adachi M
Acta Ophthalmologica 2017; 95: e720-e726
73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Boiero C
European Journal of Pharmaceutical Sciences 2017; 105: 188-194
72774 Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients
Matsuo H
Acta Ophthalmologica 2017; 95: e720-e726
73076 Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma
Shirakashi M
Advances in Therapy 2017; 34: 1438-1448
73009 Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells
Liu Y
Cornea 2017; 36: 719-724
72896 Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
Li Y
AAPS PharmSciTech 2017; 18: 2919-2926
73171 Twenty-Four-Hour Variation of Intraocular Pressure in Primary Open-Angle Glaucoma Treated with Triple Eye Drops
Horiguchi H
Journal of Ophthalmology 2017; 2017: 4398494
72975 Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
Papakonstantinou VD; Tsatsos M
Drug design, development and therapy 2017; 11: 1267-1272
72774 Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients
Togano T
Acta Ophthalmologica 2017; 95: e720-e726
73009 Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells
Chen X
Cornea 2017; 36: 719-724
73171 Twenty-Four-Hour Variation of Intraocular Pressure in Primary Open-Angle Glaucoma Treated with Triple Eye Drops
Ogawa S
Journal of Ophthalmology 2017; 2017: 4398494
73072 The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case
Guzmán ML
European Journal of Pharmaceutical Sciences 2017; 105: 188-194
